GUCY1A1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07957(GUCY1A1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07957(GUCY1A1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of GUCY1A1 Antibody**

GUCY1A1 (Guanylate Cyclase 1 Soluble Subunit Alpha 1) is a critical component of the nitric oxide (NO) signaling pathway. It forms a heterodimer with GUCY1B1 to create soluble guanylate cyclase (sGC), an enzyme that catalyzes the conversion of GTP to cyclic GMP (cGMP) upon NO binding. This cGMP-dependent signaling regulates vascular tone, platelet aggregation, and smooth muscle relaxation, playing roles in cardiovascular homeostasis, neuronal signaling, and other physiological processes. Dysregulation of GUCY1A1/sGC activity is linked to hypertension, atherosclerosis, pulmonary hypertension, and cancer progression.

GUCY1A1 antibodies are essential tools for studying the expression, localization, and function of the GUCY1A1 subunit in research. They are used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein levels in tissues or cells. Commercially available antibodies are typically raised against specific epitopes of human GUCY1A1. with cross-reactivity validated in common model organisms. Researchers also utilize these antibodies to investigate pathological mechanisms, such as altered NO-sGC-cGMP signaling in cardiovascular diseases, or to evaluate therapeutic targets like sGC stimulators/activators. Specificity validation (e.g., via knockout controls) is crucial due to structural similarities among guanylate cyclase family members.